Business
ADOCIA Announces Full Year 2025 Financial Results and Provides a Corporate and Financial Update
LYON, France, April 21, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, publishes its annual financial results as of December 31, 2025. The consolidated statements contained herein were approved by Adocia’s board of directors on April 20, 2026. Audit procedures have been completed and the audit report
About this update from Adocia Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/6f07b94188558d812c2bafef40c98ddf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gN_qggE6i8hHdXhAAzyg7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4OA--/https://media.zenfs.com/en/business-wire.com/6f07b94188558d812c2bafef40c98ddf","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/gM105RsnA0_mDJcMX6uyoQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA-/https://media.zenfs.com/en/business-wire.com/6f07b94188558d812c2bafef40c98ddf","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position of €17.2m as of December 31, 2025","length":47,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Progresses achieved with our flagship projects in 2025:","length":55,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Chinese partner Tonghua Dongbao completed BioChaperone® Lispro Phase 3 program with positive results in people with type 1 and type 2 diabetes in China, and the marketing authorization filling is in preparation","length":210,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Continued development of BioChaperone®, with two new feasibility studies in collaboration with two large pharmaceutical companies in the fields of diabetes and obesity","length":167,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Patent application filed for a new long-acting technology platform AdoXLong™, with initial positive in vitro and in vivo results generated with semaglutide","length":155,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Continued development of AdoShell® platform, with a clinical trial application submission to regulatory authorities planned for Q3 2026","length":135,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":667,"olType":false}]},{"val":[{"type":"text","content":"Post-period events:","length":19,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"A shareholder loan agreement was entered into on April 21, 2026 with Vester Finance, securing a cash runway until the begining of Q2 2027","length":137,"tagName":"p...